• Fernando Jablonka, Fernanda Schindler, Paula Philbert Lajolo, Hélio Pinczowski, Fernando Luiz Affonso Fonseca, Antônio Barbieri, Luiz Henrique Massonetto, Fábio Tadashi Katto, and Auro Del Giglio.
• Fundação e Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil.
• Sao Paulo Med J. 2009 Jan 1; 127 (1): 192219-22.

Context And ObjectiveCross-linked N-telopeptides of type I collagen (NTx) increase in concentration in situations in which bone resorption is increased, such as osteoporosis and bone metastasis (BM). We aimed to evaluate the serum concentrations of NTx in a sample of patients with several types of solid tumors.Design And SettingCross-sectional analytical study with a control group in a tertiary public hospital.MethodsWe performed the quantitative enzyme-linked immunosorbent assay (ELISA) on serum NTx levels in 19 subjects without a history of cancer and 62 patients with various solid tumors who had been referred for a bone scan. Three experienced analysts read all bone scans.ResultsThe serum NTx levels in patients with cancer and BM, with cancer but without BM and without cancer were 46.77 +/- 2.58, 32.85 +/- 2.05 and 22.32 +/- 2.90 respectively (P < 0.0001). We did not find any significant correlations of serum NTx with age, gender, history of bone pain, tumor type and bone alkaline phosphatase levels. We found a significant correlation between serum NTx and alkaline phosphatase levels (R(2) = 0.08; P = 0.022).ConclusionsSerum NTx levels are significantly higher in patients with solid tumors and bone metastases than they are in patients without bone metastases and in normal controls.

23 keywords...

hide…